Skip to content

Released Aug 1, 2022, before the open

10-Q filed Aug 1, 2022, 32 days after period end · 0001171843-22-005187

Q2 2022 · 10-Q
Revenue—
Net Income-$8.49MN/M vs Q2 2021N/M vs Q1 2022
EPS, diluted—
Operating Income-$8,987,000N/M
Operating Cash Flowderived-$4,600,000N/M
Free Cash Flowderived-$4,537,000N/M

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

MetricQ2 2022Q2 2021Q2 2020Q2 2019
Net Income-$8.49M-$55.80M-$5.56M-$8.81M
EPS Diluted—-$1.07-$0.41-$1.33

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Compass Therapeutics, Inc. · CIK 1738021 · Engraved from SEC EDGAR